You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
NYSE accepts CorMedix's plan to regain compliance with listing requirements
S&P Capital IQ Pro | Unrivaled Sector Coverage
S&P Capital IQ Pro | Powering Your Edge
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Investment Research Analysts Providing Greater Coverage on Inflation
CorMedix Inc. said the New York Stock Exchange accepted its plan to regain compliance with its listing requirements.
The Brisbane, Calif.-based company had said in June that it received a noncompliance notice from the NYSE American.
The biopharmaceutical company had reported a stockholders' equity of $800,000, lower than a minimum of $2 million as required by NYSE.
CorMedix, which submitted its plan on July 16, has until Dec. 16, 2019 to regain compliance.